• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

PLoS One . Performance of the Abbott SARS-CoV-2 IgG serological assay in South African 2 patients

tetano

Editor, Senior Moderator
PLoS One


. 2022 Feb 4;17(2):e0262442.
doi: 10.1371/journal.pone.0262442. eCollection 2022.
Performance of the Abbott SARS-CoV-2 IgG serological assay in South African 2 patients


Sarika Jugwanth[SUP] 1 2 [/SUP], Maemu P Gededzha[SUP] 1 2 [/SUP], Nakampe Mampeule[SUP] 1 2 [/SUP], Nontobeko Zwane[SUP] 1 [/SUP], Anura David[SUP] 3 [/SUP], Wendy A Burgers[SUP] 4 5 6 [/SUP], Jonathan M Blackburn[SUP] 6 7 [/SUP], Jurette S Grove[SUP] 2 8 [/SUP], Jaya A George[SUP] 2 8 [/SUP], Ian Sanne[SUP] 9 [/SUP], Lesley Scott[SUP] 2 3 [/SUP], Wendy Stevens[SUP] 2 3 [/SUP], Elizabeth S Mayne[SUP] 1 2 [/SUP]



Affiliations

Abstract

In late December 2019, pneumonia cases of unknown origin were reported in Wuhan, China. This virus was named SARS-CoV2 and the clinical syndrome was named coronavirus disease 19 (COVID-19). South Africa, despite strict and early lockdown has the highest infection rate in Africa. A key component of South Africa's response to SARSCoV2 was the rapid scale-up of diagnostic testing. The Abbott SARS-CoV2 assay detects IgG antibodies against the Nucleocapsid (N) protein of the SARS-CoV2 virus. This study undertook to validate and evaluate performance criteria of the Abbott assay and to establish whether this assay would show clinical utility in our population. Positive patients (n = 391) and negative controls (n = 139) were included. The Architect-i and Alinity-i systems were analyzers that were used to perform the SARS-CoV-2 IgG assay. In-house ELISA was incorporated into the study as a confirmatory serology test. A total of number of 530 participants was tested, 87% were symptomatic with infection and 13% were asymptomatic. When compared to RT-qPCR, the sensitivity of Architect and Alinity SARS-CoV2 assays was 69.5% and 64.8%, respectively. Specificity for Architect and Alinity assays was 95% and 90.3%, respectively. The Abbott assay was also compared to in house ELISA assay, with sensitivity for the Architect and Alinity assays of 94.7% and 92.5%, respectively. Specificity for Abbott Alinity assays was 91.7% higher than Abbott Architect 88.1%. Based on the current findings testing of IgG after 14 days is recommended in South Africa and supports other studies performed around the world.
 
Back
Top Bottom